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Background: The aim of this study was to evaluate the procedural success and early
outcomes of MitraClip implantation.
Methods: Between July 2012 and February 2013, 15 patients (12 males, 3 females;
mean age 60.8013.03; range from 35 to 78 years old) underwent MitraClip
implantation in our clinic were included. All patients had symptomatic severe func-
tional mitral regurgitation with high surgical risk or were judged to be inoperable by
heart team.
Results: The success of the procedure was 93.33%. We have successfully implanted
MitraClip device to all patients except one. One clip was implanted in 9 (64.28%)
patients, and 5 (35.71%) patients were treated with 2 clips. The mean procedure time
was 183.8480.96 minutes (range, 90–300 minutes), with a mean septal puncture
time of 36.1532.09 minutes. Following the procedure, severity of the mitral
regurgitation was decreased average 2.100.48 grade. Average functional status of
the patients improved from NYHA class 3.860.35 to 2.580.79 at 1 month follow
up. Their 6-minute walking distances improved from 276.16150.71 to
378.00168.40 meters. N terminal B-type natriuretic peptide levels decreased from
3642.263220.01 to 2025.80810.34 pg/ml. 2 patients (13.33%) died within the ﬁrst
month of follow-up due to noncardiac causes.
Conclusion: The MitraClip procedure can be performed safely to the symptomatic
patients with severe functional mitral regurgitation who have otherwise high surgical
risk or are judged to be inoperable. Our initial experience demonstrated acute echo-
cardiographic and early clinical improvement in these patients.Echocardiographic criteria for eligibility of the Mitraclip implantation
Inclusion Criteria
Coaptation length > 2 mm
Mobile posterior leaﬂet
Posterior leaﬂet length > 8 mm
No leaﬂet calciﬁcation on grasping site
Leaﬂet thickness <5 mm
Mitral valve oriﬁce area >4 cm2
Exclusion Criteria
Rheumatic valve disease
Thick interatrial septum
Active infective endocarditis
Flail leaﬂet (not an exclusion criteria if ﬂail gap<10 mm
and ﬂail width< 15 mm)Presence of cleftBaseline Demographics and Clinical Features
Age, years 60.80  13,03
Age >65 years, (%) 6 (40.0)
Male sex, (%) 12 (80.0)
Hypertension, (%) 6 (40.0)
Diabetes mellitus, (%) 5 (33.3)
Creatinine, mg/dl 1.320.40
eGFR, ml/min per 1.73 m2 57.6616.66
History of coronary artery disease, (%) 11 (73.3)
EF, % 28.73  8.75
NT-Pro BNP, pg/ml 3642.26  3220.01
LV end-diastolic diameter, mm 64.859.28
LV end-systolic diameter, mm 54.7810.82
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Introduction: Although heart transplantation is the most important option for end
stage heart failure resistant to medical therapy, new generation ventricular assist
devices have an increasing popularity in the recent years. The survival advantage
provided with these devices and improvement in long term complication rates are the
main reason of widespread usage of these devices. In this paper we want to share our
experience with the devices which are reported with better results than heart trans-
plantation in some reports.
Material - Method: new generation, long term, continuous ﬂow, intracorporeal left
ventricular device implantation was performed between December 2010 and May
2013 for 64 cases with an age average of 47.85. For 56 cases HeartWare and for
8 cases HeartMate II were used. Patients were in class 2 (clinical deterioration while
on inotropes), 3 (stable but inotrope dependent) and 4 (resting symptoms with oral
therapy) according to INTERMACS (The Interagency Registry for Mechanically
Assisted Circulatory Support) classiﬁcation. While the ischemic etiology rate was %
28.15, dilated cardiomyopathy was the etiology for the majority of the patients. In %
34.37 of the patients there was relative contraindication because of clinical situations
like ﬁxed pulmonary hypertension, diabetes with end organ damage and obesity.
Results: In-hospital mortality rate was 10.93% with 7 patients. Extracorporeal
membrane oxygenator system was needed for transient right ventricular failure in
3 cases. The most common cause of mortality was multiorgan failure and sepsis due to
right ventricular failure. Preoperative cardiogenic shock (INTERMACS 1) was found
risk factor for mortality. In long term follow up, 5 cases were bridged to trans-
plantation, three cases were lost (2 intracerebral hemorrhage, 1 pancreatic cancer).
Except 1 transient ischemic attack, there was no thromboembolic complication. there
were 3 device thrombosis, which of two were treated completely with intraventricular
thrombolitic therapy under scopy and one was treated with surgical pump change. The
remaining patients still on support are stable and asymptomatic.
Discussion: With the improvements of new generaiton support systems, outcome of
these devices are changing for the better day by day and the new generation devices
are becoming an alternative therapy competing with heart failure in many hopeless
circumstances.
OP-098
Ventricular Support Systems for End Stage Heart Failure Patients: Which
patient, When?
Yaprak Engin1, Çagatay Engin1, Tahir Yagdı1, Serkan Ertugay1, Sanem Nalbantgil2,
Mehdi Zoghi2, Özlem Balcıoglu1, Pelin Öztürk1, Mustafa Özbaran1
1Ege University, Department of Cardiovascular Surgery, Izmir, 2Ege University,
Department of Cardiology, Izmir
Introduction: The improvements of medical and surgical therapy for heart failure
have been increasing especially in the last two decades. With these improvements, the
patient proﬁle is changing continuously with an increasing number. Ventricular
support systems have been marked a new era in heart failure therapy, a chance of
survival until transplantation and a new hope for the patients that are unsuitable for
transplantation. The optimal timing of implantation seems to be the most important
issue for postoperative success. With this paper, we report our data of ventricular
support system implantation timing for heart failure patients and its effects on
outcome.
Material - Method: total of 118 heart failure patients which were implanted long term
support systems in our institution between 2008 – 2013 were included. The clinical
condition of the patients were evaluated with INTERMACS (The Interagency
Registry for Mechanically Assisted Circulatory Support) classiﬁcation. Accordingly,
prior to operation, 20.33% of the patients were in INTERMACS 1 (cardiogenic
shock), 27,96% were in INTERMACS 2 (clinical deterioration on inotropes), 48,30%
were in INTERMACS 3 (inotrope dependency), 2.54% were in INTERMACS 4
(symptoms in resting despite oral therapy).
Results: In-hospital mortality of patients in INTERMACS 1 were 37.5%, in
INTERMACS 2 were 18.18%, in INTERMACS 3 were 8.77%, while there was no
early mortality in INTERMACS 4 patients.
Discussion: As the clinical deterioration of end-stage heart failure patients deepens,
ın-hospital mortality rates rise. For this reason, the referral of these patients to
transplantation centers before the development of biventricular heart failure is crucial.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
